Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoPalAna-style neoadjuvant biomarker study of palbociclib plus endocrine therapy in ER-positive/HER2-negative breast cancer
2016-000879-24Phase 2Completed
- Sponsor
- Institut Jules Bordet
- Start
- Feb 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib, letrozole, tamoxifen and goserelin in breast cancer, sponsored by Institut Jules Bordet. Primary endpoint: Baseline transcriptomic profile of resistance to 4 months of palbociclib and endocrine therapy defined as stable or progressive disease by ultrasound based on WHO criteria. Started Feb 2017; status: completed.
02
Drugs
palbociclibletrozoletamoxifengoserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-000879-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000879-24.